P67

Q3 Medicine Ejc Supplements Pub Date : 2015-11-01 DOI:10.1016/j.ejcsup.2015.08.014
O. Bryzgunova , E. Lekhnov , T. Skvortsova , E. Morozkin , I. Zaporozhchenko , A. Grigorieva , M. Zaripov , E. Ryabchikova , V. Vlassov , P. Laktionov
{"title":"P67","authors":"O. Bryzgunova ,&nbsp;E. Lekhnov ,&nbsp;T. Skvortsova ,&nbsp;E. Morozkin ,&nbsp;I. Zaporozhchenko ,&nbsp;A. Grigorieva ,&nbsp;M. Zaripov ,&nbsp;E. Ryabchikova ,&nbsp;V. Vlassov ,&nbsp;P. Laktionov","doi":"10.1016/j.ejcsup.2015.08.014","DOIUrl":null,"url":null,"abstract":"<div><p>Differently sized microparticles, including exosomes (30–100<!--> <!-->nm), prostasomes (50–500<!--> <!-->nm), oncosomes (50–500<!--> <!-->nm) and other microparticles (100–1000<!--> <!-->nm) were found in blood and urine. Exosomes from prostate cancer (PCa) patients can potentially contain cancer-specific nucleic acids, and thus can represent a valuable source of diagnostic material. In this study, we have investigated microvesicles and miRNA from urine of healthy donors and PCa patients. To isolate miRNAs from urine and microparticles, novel methods for miRNA isolation were elaborated (Rus. patent application No 2014137763, priority date 17.09.2014). The study population included 14 patients with PCa (63–82<!--> <!-->years, T2-3NxMx1) and control group of 20 healthy volunteers with no previous history of prostate disease (48–73<!--> <!-->years). Urine was clarified by two serial centrifugations at 400<em>g</em>, 20<!--> <!-->°C, 20<!--> <!-->min and at 17000<em>g</em>, 20<!--> <!-->°C, 20<!--> <!-->min. Microparticles were precipitated from the resulting supernatant by high-speed centrifugation at 100000<em>g</em>, 18<!--> <!-->°C, 90<!--> <!-->min, the pellet was resuspended and pelleted by centrifugation under the same conditions. To isolate exosomes, total microparticles were filtered through 0.1<!--> <!-->μm pore filters and reprecipitated. The resulting pellets were resuspended and exosome samples were investigated by transmission electron microscopy (TEM). MiRNAs were isolated by one-step single-phase protocol and purified using “BioSilica” spin- columns (Zaporozhchenko et al., Anal. Biochem, upcoming, doi: 10.1016/j.ab.2015.03.028) and by recently developed method based on precipitation of excess biopolymers, allowing to isolate miRNAs with better efficiency than commercially available kits. The size and quantity assessment of extracellular RNA were performed using capillary electrophoresis system on Agilent 2100 Bioanalyzer. Concentrations of miRNAs (miR19b, miR25, miR205, miR125b, miR126) were measured by qRT-PCR and normalized to miR-16 using dCq method.</p><p>TEM demonstrated the presence of 20–300<!--> <!-->nm microparticles in urine of healthy donors and PCa patients. Approximately 50–70% of all urine microparticles are represented by 30–100<!--> <!-->nm exosomes and residual 30–50% by particles larger than 100<!--> <!-->nm. (The pool of urine microvesicles consists of 50–70% exosomes and 30–50% particles larger than 100<!--> <!-->nm.).</p><p>The major part of extracellular RNA found both in exosomes and total microparticles fraction of healthy donors and patients with PCa, is 25–200<!--> <!-->nt long and can include tRNA (73–93<!--> <!-->n.), 5.8 rRNA (∼150 n.), snoRNK (10–20 n.), snRNA (60–300<!--> <!-->n.) piRNAs (29–30 n.), miRNAs (20–25 n.), siRNA (21–25 n.). Concentration of extracellular urine RNA in exosomes and total microparticles of healthy donors and patients with PCa amounts to100<!--> <!-->pg/ml of urine on average.Receiver Operating Characteristic (ROC) curve analysis of all miRNAs in samples isolated from total urine did not demonstrate any diagnostic significance. In contrast, in training cohort concentration of miR-19b in exosomes and total microparticles fraction provide 95%/75% and 93%/100% sensitivity and specificity, respectively.</p><p>Thus, microparticles, isolated from urine of PCa patients represent a valuable source of diagnostically significant miRNAs. To investigate miR-19b, a large testing cohort is required. Search for other potential miRNA-markers by microarray profiling of cell-free miRNA isolated from urine of PCa patients is also required to reveal a sold set of markers for confident PCa diagnostics.</p></div>","PeriodicalId":11675,"journal":{"name":"Ejc Supplements","volume":"13 1","pages":"Page 8"},"PeriodicalIF":0.0000,"publicationDate":"2015-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ejcsup.2015.08.014","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ejc Supplements","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1359634915000154","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Differently sized microparticles, including exosomes (30–100 nm), prostasomes (50–500 nm), oncosomes (50–500 nm) and other microparticles (100–1000 nm) were found in blood and urine. Exosomes from prostate cancer (PCa) patients can potentially contain cancer-specific nucleic acids, and thus can represent a valuable source of diagnostic material. In this study, we have investigated microvesicles and miRNA from urine of healthy donors and PCa patients. To isolate miRNAs from urine and microparticles, novel methods for miRNA isolation were elaborated (Rus. patent application No 2014137763, priority date 17.09.2014). The study population included 14 patients with PCa (63–82 years, T2-3NxMx1) and control group of 20 healthy volunteers with no previous history of prostate disease (48–73 years). Urine was clarified by two serial centrifugations at 400g, 20 °C, 20 min and at 17000g, 20 °C, 20 min. Microparticles were precipitated from the resulting supernatant by high-speed centrifugation at 100000g, 18 °C, 90 min, the pellet was resuspended and pelleted by centrifugation under the same conditions. To isolate exosomes, total microparticles were filtered through 0.1 μm pore filters and reprecipitated. The resulting pellets were resuspended and exosome samples were investigated by transmission electron microscopy (TEM). MiRNAs were isolated by one-step single-phase protocol and purified using “BioSilica” spin- columns (Zaporozhchenko et al., Anal. Biochem, upcoming, doi: 10.1016/j.ab.2015.03.028) and by recently developed method based on precipitation of excess biopolymers, allowing to isolate miRNAs with better efficiency than commercially available kits. The size and quantity assessment of extracellular RNA were performed using capillary electrophoresis system on Agilent 2100 Bioanalyzer. Concentrations of miRNAs (miR19b, miR25, miR205, miR125b, miR126) were measured by qRT-PCR and normalized to miR-16 using dCq method.

TEM demonstrated the presence of 20–300 nm microparticles in urine of healthy donors and PCa patients. Approximately 50–70% of all urine microparticles are represented by 30–100 nm exosomes and residual 30–50% by particles larger than 100 nm. (The pool of urine microvesicles consists of 50–70% exosomes and 30–50% particles larger than 100 nm.).

The major part of extracellular RNA found both in exosomes and total microparticles fraction of healthy donors and patients with PCa, is 25–200 nt long and can include tRNA (73–93 n.), 5.8 rRNA (∼150 n.), snoRNK (10–20 n.), snRNA (60–300 n.) piRNAs (29–30 n.), miRNAs (20–25 n.), siRNA (21–25 n.). Concentration of extracellular urine RNA in exosomes and total microparticles of healthy donors and patients with PCa amounts to100 pg/ml of urine on average.Receiver Operating Characteristic (ROC) curve analysis of all miRNAs in samples isolated from total urine did not demonstrate any diagnostic significance. In contrast, in training cohort concentration of miR-19b in exosomes and total microparticles fraction provide 95%/75% and 93%/100% sensitivity and specificity, respectively.

Thus, microparticles, isolated from urine of PCa patients represent a valuable source of diagnostically significant miRNAs. To investigate miR-19b, a large testing cohort is required. Search for other potential miRNA-markers by microarray profiling of cell-free miRNA isolated from urine of PCa patients is also required to reveal a sold set of markers for confident PCa diagnostics.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
P67
在血液和尿液中发现不同大小的微颗粒,包括外泌体(30-100 nm)、前列腺体(50-500 nm)、癌体(50-500 nm)和其他微颗粒(100-1000 nm)。前列腺癌(PCa)患者的外泌体可能含有癌症特异性核酸,因此可以代表有价值的诊断材料来源。在这项研究中,我们研究了健康供体和PCa患者尿液中的微囊泡和miRNA。为了从尿液和微粒中分离miRNA,研究了分离miRNA的新方法。专利申请号:2014137763,优先权日:2014年9月17日)。研究人群包括14例PCa患者(63-82岁,T2-3NxMx1)和20名无前列腺病史的健康志愿者(48-73岁)作为对照组。在400g、20℃、20 min和17000g、20℃、20 min连续两次离心澄清尿液,在100000g、18℃、90 min高速离心沉淀所得上清液中的微粒,在相同条件下重悬并离心成球。为了分离外泌体,总微粒通过0.1 μm孔过滤器过滤并再沉淀。将所得微球重悬,并通过透射电子显微镜(TEM)研究外泌体样品。mirna通过一步单相分离,并使用“BioSilica”自旋柱纯化(Zaporozhchenko等,Anal。生物化学,即将出版,doi: 10.1016/j.ab.2015.03.028),并通过最近开发的基于过量生物聚合物沉淀的方法,允许以比市售试剂盒更高的效率分离mirna。在Agilent 2100生物分析仪上用毛细管电泳系统对细胞外RNA的大小和数量进行评估。采用qRT-PCR检测mirna (miR19b、miR25、miR205、miR125b、miR126)的浓度,并采用dCq法归一化为miR-16。透射电镜显示,在健康供体和前列腺癌患者的尿液中存在20-300 nm的微粒。大约50-70%的尿液微粒由30-100 nm的外泌体代表,剩余的30-50%由大于100 nm的颗粒代表。(尿微泡池由50-70%的外泌体和30-50%的大于100 nm的颗粒组成)。在健康供体和PCa患者的外泌体和总微粒部分中发现的细胞外RNA的主要部分是25-200 nt长,包括tRNA (73-93 n.), 5.8 rRNA (~ 150 n.), snoRNK (10-20 n.), snRNA (60-300 n.) pirna (29-30 n.), mirna (20-25 n.), siRNA (21-25 n.)。健康供体和前列腺癌患者外泌体和总微粒的细胞外尿RNA浓度平均为100 pg/ml。从全尿中分离的所有mirna样本的受试者工作特征(ROC)曲线分析没有显示任何诊断意义。相比之下,在训练队列中,外泌体中miR-19b的浓度和总微粒分数分别提供95%/75%和93%/100%的敏感性和特异性。因此,从PCa患者尿液中分离出的微粒代表了具有诊断意义的mirna的宝贵来源。为了研究miR-19b,需要一个大的测试队列。还需要通过从PCa患者尿液中分离的无细胞miRNA的微阵列分析来寻找其他潜在的miRNA标记物,以揭示一套可靠的PCa诊断标记物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ejc Supplements
Ejc Supplements 医学-肿瘤学
自引率
0.00%
发文量
0
审稿时长
3.7 months
期刊介绍: EJC Supplements is an open access companion journal to the European Journal of Cancer. As an open access journal, all published articles are subject to an Article Publication Fee. Immediately upon publication, all articles in EJC Supplements are made openly available through the journal''s websites. EJC Supplements will consider for publication the proceedings of scientific symposia, commissioned thematic issues, and collections of invited articles on preclinical and basic cancer research, translational oncology, clinical oncology and cancer epidemiology and prevention. Authors considering the publication of a supplement in EJC Supplements are requested to contact the Editorial Office of the EJC to discuss their proposal with the Editor-in-Chief. EJC Supplements is an official journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO) and the European Society of Mastology (EUSOMA).
期刊最新文献
99mTc/123I Dual-Radionuclide Correction for Self-Scatter, Down-Scatter, and Tailing Effect for a CZT SPECT with Varying Tracer Distributions. Pre-COVID-19 Disparities in Telemedicine Use Among Louisiana Medicaid Beneficiaries. The importance of basal-temporal white matter to pre- and post-surgical naming ability in temporal lobe epilepsy. Editorial board Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1